There is strong evidence from studies using various patient-reported outcome measures that migraine treatment with anti-CGRP/rec mAbs improves quality of life, disability and work productivity, and reduces health resource utilization as well as the expense for acute medications [2, 118]. This evidence concerns the gene CALCA and migraine disorder.